Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

Senators Durbin and Grassley proposed the new regulations for direct-to-consumer pharma advertising.

The latest news for pharma industry insiders.

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in vaccine rates.

Dr. Shakthi Kumar, EDETEK, Inc.'s Chief Strategy and Business Officer, explores the company's launch of R&D Cloud.

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought to market last year.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung cancer who are PD-1 checkpoint inhibitor resistant.

The two organizations will provide multi-modal learning experiences, opportunities to work with peers, and more.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant depression.

The two companies will combine existing assets in order to find new connections and opportunities.

The new app provides user with more features, including an AI-powered search, than the pharmacy’s previous app.

In early phase trials innovative designs offer potential for improvements in efficiency and decision-making.

The latest news for pharma industry insiders.

Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.

Casey McPherson, Founder and CEO of AlphaRose Therapeutics (formerly Chrysalis Genetics), talks about his daughter's rare genetic condition, and how it led him to antisense oligonucleotides (ASOs) and therapeutic development for rare diseases.

Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results from the ADRIATIC trial, in which patients were treated with Imfinzi for limited-stage small cell lung cancer.

Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.

The new Medicare alternative payment model aims to improve dementia care coordination.

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney disease, kidney failure, and cardiovascular death in patients treated with Ozempic.

Paul Howe, chief commercial officer at Protega Pharma, discusses recent rule changes and how the industry is impacted by them.

The senior vice president at Lilly Immunology Development discusses recent developments with Omvoh.

Prescription data between 2017 and 2023 revealed that while Adderall prescription fills decreased following the shortage, many children transitioned to alternative stimulants for attention-deficit/hyperactivity disorder.

The latest news for pharma industry insiders.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression.